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Abstract
Purpose: Glycine and serine are well-known, classic metabolites of glycolysis. Here, we profiled the expression of enzymes
associated with serine/glycine metabolism in different molecular subtypes of breast cancer and discuss their potential
clinical implications.
Methods: We used western blotting and immunohistochemistry to examine five serine-/glycine-metabolism–associated
proteins (PHGDH, PSAT, PSPH, SHMT, and GLDC) in six breast cancer cell lines and 709 breast cancer cases using tissue
microarray (TMA).
Results: PHGDH and PSPH, associated with serine metabolism, were highly expressed in the TNBC cells. GLDC, associated
with glycine metabolism, was highly expressed in HER-2-positive MDA-MB-453 and TNBC-related MDA-MB-435S. TMA
showed that the TNBC-type breast cancer tissues highly expressed PHGDH, PSPH, and SHMT1, but not the luminal-A-type
tissues (p,0.001). PSPH and SHMT1 expression in the tumor stroma of HER-2-type cancers was the highest, but the luminal-
A tissues showed the lowest expression (p,0.001). GLDC was most frequently expressed in cancer cells and stroma of the
HER-2-positive cancers and least frequently in TNBC (p,0.001). By Cox multivariate analysis, tumor PSPH positivity (hazard
ratio [HR]: 2.068, 95% confidence interval [CI]: 1.049–4.079, p = 0.036), stromal PSPH positivity (HR: 2.152, 95% CI: 1.107–
4.184, p = 0.024), and stromal SHMT1 negativity (HR: 2.142, 95% CI: 1.219–3.764, p = 0.008) were associated with short overall
survival.
Conclusions: Expression of serine-metabolism–associated proteins was increased in TNBC and decreased in the luminal-A
cancers. Expression of glycine-metabolism–associated proteins was high in the tumor and stroma of HER-2-positive cancers.
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Introduction
The ‘‘Warburg effect’’ explains a much higher rate of glycolysis
followed by fermentation in the cancer cell mitochondria.
According to the Warburg effect, glycolytic intermediates,
especially those involved in glycine and serine metabolism, rapidly
accumulate in cancer cells [1]. In serine biosynthesis, 3-phospho-
glycerate (3PG) produced by glycolysis is oxidized to 3-phospho-
hydroxypyruvate (pPYR) by phosphoglycerate dehydrogenase
(PHGDH), and then pPYR is transaminated to phosphoserine
(pSER) by phosphoserine aminotransferase (PSAT). Finally, pSER
is dephosphorylated to serine by phosphoserine phosphatase
(PSPH). In glycine metabolism, glycine is converted to methyle-
netetrahydrofolate by glycine decarboxylase (GLDC). On the
other hand, serine hydroxymethyltransferase (SHMT) converts
serine to glycine reversibly, linking the respective metabolic
pathways. According to previous reports, these enzymes are highly
expressed in several human tumors: PHGDH in breast cancer and
melanoma [2,3] and GLDC in lung cancer [4]. Therefore, they
likely play important roles in tumorigenesis [2,3,4,5].
Breast cancer is heterogeneous because it shows disparate
clinical, histopathological, and genetic characteristics. Classifica-
tion of breast cancer is actively underway to identify common
characteristics amongst the various subtypes. Breast cancer
subtypes include the luminal-A, luminal-B, HER-2, normal-
breast-like, and basal-like types defined by gene-profiling analyses
[6,7]. Another type, which is negative for estrogen receptor (ER),
progesterone receptor (PR), and HER-2—all used as biomarkers
in breast cancer treatment—is defined as the triple-negative breast
cancer (TNBC) [8].
We believe that metabolic characteristics specific to each
subtype could present distinctive hallmarks because each type
differs histopathologically, clinically, therapeutically, and prog-
nostically. High levels of glucose transporter 1 (GLUT-1) and
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carbonic anhydrase 9 (CA9), glycolysis-associated enzymes, were
found in the basal-like type and TNBC subtype [9,10], but
expression of glutaminolysis-associated proteins was increased in
the HER-2 type [11]. However, few studies have established
expression profiling of enzymes associated with serine/glycine
metabolism in breast cancer to support a molecular relationship
between subtypes and their respective metabolic characteristics. In
this study, we profiled the expression of several enzymes associated
with serine/glycine metabolism and explored their potential
clinical significance. These included PHGDH, PSAT, PSPH,
SHMT, and GLDC.
Materials and Methods
Cells and cell culture
Six breast cancer cell lines, MCF-7, MDA-MB-361, MDA-MB-
453, MDA-MB-435S, MDA-MB-231, and MDA-MB-468 (all
from the American Type Culture Collection), were examined.
MCF-7 was maintained in Dulbecco’s Modified Eagle’s Medium/
Nutrient Mixture F12 (DMEM/F12; Gibco) without phenol red,
but supplemented with 10 mg/mL insulin (Sigma), 10% fetal
bovine serum (Gibco), and 1% penicillin/streptomycin (Gibco).
The other cells were maintained in DMEM/F12 containing 10%
fetal bovine serum and 1% penicillin/streptomycin. All cells were
cultured at 37uC in a humidified atmosphere containing 5% CO2.
Western blotting
For western blotting, ,86105 cells were seeded in 60-mm
dishes. After 24 h, cells were washed twice with cold phosphate-
buffered saline and lysed in the lysis buffer (50 mM Tris-HCL [pH
7.9], 100 mM NaCl, 1 mM EDTA, 2% SDS, 0.1 mM EDTA,
and 0.1 mM EGTA) containing a protease and phosphatase
inhibitor cocktail (Thermo Scientific). Twenty micrograms of
protein was treated with Laemmli sample buffer, heated at 100uC
for 5 min, and resolved on 8% or 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. Gels were electroblotted onto
nitrocellulose membranes (GE Healthcare life-Sciences), which
were blocked in 5% non-fat dry milk in TBS-T, and incubated
with antibodies for PHGDH, PSAT1, PSPH, SHMT1, GLDC (all
at 1:1000, obtained from Abcam), or b-actin (1:2000, Sigma)
overnight at 4uC. Membranes were subsequently washed thrice in
TBS-T and probed with peroxidase-conjugated goat anti-mouse
IgG (1:2000, Santa Cruz) for 1 h at room temperature.
Membranes were washed again and developed using a chemilu-
minescent reagent (ECL; GE Healthcare Life Sciences, Inc.). Band
densities were measured using TINA imaging software (Raytest,
Straubenhardt, Germany).
Patient selection
The institutional review board of Yonsei University Severance
Hospital approved this retrospective study. The study population
included 709 patients who had been diagnosed histopathologically
with invasive ductal carcinoma before tumor excision at Yonsei
University Severance Hospital from 2002 to 2006. Patients who
had received hormone therapy or chemotherapy before surgery
were excluded. This study was approved by the Institutional
Review Board (IRB) of Yonsei University Severance Hospital. IRB
Table 1. Source, clone, and dilution of antibodies.
Antibody Company Clone Dilution
serine/glycine metabolism related proteins
PHGDH Abcam, Cambridge, UK Polyclonal 1:100
PSAT1 Abcam, Cambridge, UK Polyclonal 1:100
PSPH Abcam, Cambridge, UK Polyclonal 1:100
SHMT Abcam, Cambridge, UK Polyclonal 1:100
GLDC Abcam, Cambridge, UK Polyclonal 1:100
molecular subtype related proteins
ER Thermo Scientific, San Siego, CA, USA SP1 1:100
PR DAKO, Glostrup, Denmark PgR 1:50
HER-2 DAKO, Glostrup, Denmark Polyclonal 1:1500
Ki-67 Abcam, Cambridge, UK MIB 1:1000
doi:10.1371/journal.pone.0101004.t001
Figure 1. Expression of enzymes associated with serine/glycine
metabolism in breast cancer cells detected by western
blotting. PHGDH and PSPH levels were increased in the TNBC cell
lines and the GLDC levels was increased in MDA-MB-453 of the HER-2
subtype and MDA-MB-435S of the TNBC subtype. SHMT1 was highly
expressed in the HER-2 subtype and MDA-MB-435S cells.
doi:10.1371/journal.pone.0101004.g001
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waived the informed consent form from patients. Patient records/
information was anonymized and de-identified prior to analysis.
Patients’ tissue samples were fixed in 10% buffered formalin and
embedded in paraffin. Archival tissues stained with hematoxylin
and eosin (H&E) were reviewed by three breast pathologists (SK
Kim, WH Jung, and JS Koo). Histopathology grading was done
according to the Nottingham grading system [12]. Patients’
clinicopathological characteristics included age at initial diagnosis,
lymph-node metastasis, tumor recurrence, distant metastasis, and
survival.
Tissue microarray
A random area was selected on an H&E-stained tissue slide and
the corresponding area was marked on the surface of the
corresponding paraffin-embedded tissue block. The selected area
was punctured using a biopsy needle, and a 3-mm tissue core was
extracted and transferred onto a 665 recipient block. Two tissue
cores were extracted to minimize extraction bias. Each tissue core
was assigned a unique tissue microarray location number that was
linked to a database recording other clinicopathological data.
Immunohistochemistry
Antibodies used are shown in Table 1. Immunostaining was
performed using formalin-fixed, paraffin-embedded (FFPE) tissue
sections. Briefly, 5-mm-thick sections were cut using a microtome,
transferred onto adhesive slides, and dried at 62uC for 30 min.
After incubation with primary antibodies, immunodetection was
performed using biotinylated anti-mouse immunoglobulin, fol-
lowed by streptavidin-conjugated peroxidase from a streptavidin–
biotin kit. 3,39-Diaminobenzidine was used as the chromogen
substrate. Incubation with the primary antibody was omitted for
the negative controls. Positive control tissue samples were used as
recommended by the manufacturer. Slides were counterstained
with Harris hematoxylin.
Interpretation of immunohistochemical staining
Light microscopy was used to visualize the expression of
immunohistochemical markers. Pathological status, including ER,
PR, and HER-2 positivity were gathered using patients’ pathologic
reports. A cut-off value of .1% positively stained nuclei was used
to define ER and PR positivity [13]. HER-2 staining was analyzed
according to guidelines by the American Society of Clinical
Oncology (ASCO)/College of American Pathologists (CAP): 0 =
no immunostaining; 1+= weak incomplete membranous staining
of ,10% of tumor cells; 2+= complete membranous staining,
either uniform or weak, of $10% of tumor cells; and 3+=
uniform intense membranous staining of $30% of tumor cells
[14]. HER-2 immunostaining was considered positive when strong
(3+) membranous staining was observed whereas cases with 0 to 1+
were regarded as negative. Cases showing 2+ HER-2 expression
were further examined by fluorescent in situ hybridization (FISH)
for HER-2 amplification.
For measuring immunostaining intensity, we divided breast
cancers into four groups as follows: 0 (negative), 1 (weakly positive),
2 (moderately positive), and 3 (strongly positive). For measuring
the proportion of stained cells, we divided breast cancers into three
groups as follows: 0 (negative), 1 (positive ,30%), and 2 (positive
.30%). Immunohistochemical values for GLDC, PSAT, PSPH,
PHGDH, and SHMT were calculated by multiplying immuno-
staining intensity to the proportion of stained cells. The final score
after multiplication was classified as follows: 0–1 as negative and
2–6 as positive [15]. Ki-67 labeling index (LI) was defined as the
percentage of cells with positive nuclei to total number of
cancerous cells.
Tumor phenotype classification
Breast cancer phenotypes were classified according to immu-
nohistochemical results for ER, PR, HER-2, and Ki-67 and HER-
2 FISH results as follows [16]: luminal A type: ER and/or PR
positive, HER-2 negative, and Ki-67 LI ,14%; luminal B type:
(HER-2 negative) ER and/or PR positive, HER-2 negative, and
Ki-67 LI$14%, (HER-2 positive) ER and/or PR positive, HER-2
overexpressed and/or amplified; HER-2 overexpression type: ER and
PR negative and HER-2 overexpressed and/or amplified; and
TNBC type: ER, PR, and HER-2 negative.
FFPE tissue microdissection and protein extraction
Hematoxylin-stained, uncovered slides were prepared using
FFPE tissue blocks of five breast cancer cases of each molecular
subtype. Tumor components or the corresponding stroma was
then captured using laser microdissection (LMD 6500, Leica,
Wetzlar, Germany). Microdissected FFPE tissues were deparaffi-
nized in xylene and rehydrated in a graded series of alcohol. Total
protein was extracted from the captured microdissected FFPE
material using the Qproteome FFPE Tissue Kit (Qiagen, Hilden,
Germany). Samples were mixed with the FFPE extraction buffer
EXB Plus (100 ml per sample), incubated at 100uC for 20 min, at
80uC for 2 h, and finally centrifuged at 14,000 g at 4uC for
15 min. The resultant supernatants were measured by the
Bradford assay (Bio-Rad, USA) to determine protein concentra-
tion.
Figure 2. Western blotting detection of enzymes associated
with serine/glycine metabolism in breast cancer tissues. PHGDH
levels were the highest in the epithelial component of the TNBC and
the lowest in the epithelial component of the luminal-A subtype. PSPH
and SHMT1 expressions were decreased in the luminal-A subtype. GLDC
expression was the highest in the tumor epithelial compartment of the
luminal-B subtype and in the stromal compartment of the HER-2
subtype.
doi:10.1371/journal.pone.0101004.g002
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Statistical analyses
Data were analyzed using the SPSS software (Version 12.0;
SPSS Inc., Chicago, IL, USA) for Microsoft Windows. Statistical
significance was established by the Student’s t and Fisher’s exact
tests for continuous and categorical variables, respectively. A
corrected p-value and the Bonferroni method were used for
multiple comparisons. Statistical significance was when p,0.05.
Kaplan–Meier survival curves and log-rank statistics were used to
evaluate time to tumor recurrence and overall survival. Multivar-
iate regression analysis was performed using the Cox proportional-
hazards model.
Results
Detection of enzymes associated with serine/glycine
metabolism in cell lines
Western blotting of enzymes associated with serine/glycine
metabolism in six human breast cancer cell lines is presented in
Figure 1. The density of each protein was calculated relative to
b-actin and assessed in relation to the molecular subtypes of the
tested cell lines: MCF-7 and MDA-MB-361 representing the
luminal type; MDA-MB-453, HER-2 type; and MDA-MB-453S,
MDA-MB-231, and MDA-MB-468, TNBC type. We confirmed
that these proteins were expressed in cell lines of the luminal,
HER-2, and TNBC types.
Detection of enzymes associated with serine/glycine
metabolism in patients’ specimens
Next, expression of the abovementioned proteins was examined
in patients’ specimens and correlated to the corresponding
molecular subtypes. Each tumor tissue was divided into epithelial
and the corresponding stromal components by laser microdissec-
tion. Protein expression profiles were compared between the
epithelial and stromal components in each cancer subtype
(Figure 2). All serine-metabolism–associated enzymes were ex-
pressed to a greater extent in the epithelial than in the stromal
component of the HER-2 and TNBC types. GLDC was expressed
to a greater extent in the epithelial rather than in the stromal
Table 2. Patients’ clinicopathological characteristics according to breast cancer phenotype.
Parameters
Total (n = 709)
(%)
Luminal A (n =297)
(%)
Luminal B (n=168)
(%)
HER-2 (n=70)
(%)
TNBC (n=174)
(%) P-value
Age (yr, mean 6SD) 49.7610.9 50.5610.5 48.4610.0 52.4610.0 48.2612.5 0.011
Histologic grade ,0.001
I 119 (16.7) 90 (30.3) 19 (11.3) 1 (1.4) 7 (4.0)
II 360 (50.6) 179 (60.3) 92 (54.8) 36 (51.4) 53 (30.5)
III 232 (32.6) 28 (9.4) 57 (33.9) 33 (47.1) 114 (65.5)
Tumor stage 0.014
T1 346 (48.7) 162 (54.5) 86 (51.2) 30 (42.9) 66 (37.9)
T2 350 (49.2) 127 (42.8) 80 (47.6) 39 (55.7) 104 (59.8)
T3 15 (2.1) 8 (2.7) 2 (1.2) 1 (1.4) 4 (2.3)
Nodal stage 0.055
N0 420 (59.1) 170 (57.2) 92 (54.8) 42 (60.0) 115 (66.1)
N1 188 (26.4) 86 (29.0) 43 (25.6) 13 (18.6) 45 (25.9)
N2 64 (9.0) 26 (8.8) 18 (10.7) 10 (14.3) 10 (5.7)
N3 39 (5.5) 15 (5.1) 15 (8.9) 5 (7.1) 4 (2.3)
Estrogen receptor status ,0.001
Negative 254 (35.7) 5 (1.7) 5 (3.0) 70 (100.0) 174 (100.0)
Positive 457 (64.3) 292 (98.3) 163 (97.0) 0 (0.0) 0 (0.0)
Progesterone receptor status ,0.001
Negative 339 (47.7) 48 (16.2) 48 (28.6) 69 (98.6) 174 (100.0)
Positive 372 (52.3) 249 (83.8) 120 (71.4) 1 (1.4) 0 (0.0)
HER-2 status ,0.001
0 262 (36.8) 107 (36.0) 24 (14.3) 0 (0.0) 129 (74.1)
1+ 184 (25.9) 119 (40.1) 33 (19.6) 0 (0.0) 32 (18.4)
2+ 141 (19.8) 71 (23.9) 41 (24.4) 16 (22.9) 13 (7.5)
3+ 124 (17.4) 0 (0.0) 70 (41.7) 54 (77.1) 0 (0.0)
Ki-67 LI (%, mean 6SD) 17.4618.4 4.763.7 19.5612.4 19.7612.9 36.1622.9 ,0.001
Tumor recurrence 63 (8.9) 14 (4.7) 13 (7.7) 12 (17.1) 24 (13.8) 0.001
Patients’ death 59 (8.3) 12 (4.0) 12 (7.1) 12 (17.1) 23 (13.2) ,0.001
Duration of clinical follow-up
(months, mean 6SD)
69.9631.2 72.7629.6 70.1630.1 64.9634.1 67.0633.5 0.127
TNBC, triple negative breast cancer.
doi:10.1371/journal.pone.0101004.t002
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component of the luminal-B, HER-2, and TNBC types; however,
the opposite pattern was observed in the luminal-A cancers.
Patients’ clinicopathological characteristics
Breast cancer tissues included in the TMA analysis were
classified into luminal A (297 cases, 41.9%), luminal B (168 cases,
23.7%), HER-2 (70 cases, 9.9%), or TNBC (174 cases, 24.5%;
Table 2). Notably, the TNBC type demonstrated higher
histopathological grading (p,0.001), higher T staging
(p = 0.014), and higher Ki-67 LI (p,0.001) than the other
subtypes. Whereas, the HER-2 type occurred in older patients
Figure 3. Expression of enzymes associated with serine/glycine metabolism in different molecular breast cancer subtypes. PHGDH
levels were increased in the epithelial component of the HER-2 and TNBC subtypes. PSPH was increased in the tumor epithelium of the TNBC subtype
and in the HER-2 stroma. SHMT1 expression was high in the epithelial component of the TNBC subtype and in the stromal component of the luminal-
B and HER-2 subtypes. GLDC was high in the epithelial and stromal components of the HER-2 subtype.
doi:10.1371/journal.pone.0101004.g003
Figure 4. Expression heat map showing levels of enzymes associated with serine/glycine metabolism according to breast cancer
molecular subtype.
doi:10.1371/journal.pone.0101004.g004
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(p = 0.011), more frequently recurred, and resulted in higher death
rates (p = 0.001) than the other types (Table 2).
Expression profiling of metabolism-associated enzymes
in relation to cancer phenotypes
Serine-/glycine-metabolism–associated proteins were investigat-
ed in cancer tissues by immunohistochemistry (Figure 3, Figure 4
and Table 3). PHGDH, PSPH, and SHMT1 were highly
expressed in the epithelial component of the TNBC subtype.
However, expression was the lowest in the luminal-A subtype (p,
0.001). Similarly, the stromal component expressed the highest
PSPH and SHMT1 levels in the HER-2, but the lowest in the
luminal-A subtype (p,0.001).
GLDC ranked the highest, in both the epithelial and stromal
components, in the HER-2 subtype, but the lowest in TNBC (p,
0.001).
Correlations between protein expression and patients’
clinicopathological characteristics
After assessing expression profiles of the tested proteins, we
examined whether expression profiles were correlated with
patients’ clinicopathological characteristics (Table 4 and Table 5).
High levels of PHGDH, PSPH, SHMT1 in tumor and PSPH in
tumor stroma were correlated with high histological grading (p,
0.001), ER negativity (p,0.001), PR negativity (p,0.001), and
high Ki-67 LI (p,0.001). High levels of SHMT1 and GLDC in
the stromal component were correlated with HER-2 positivity (p,
0.001). Expression of stromal PSPH was associated with higher T
staging (p= 0.048), whereas expression of tumor GLDC was
associated with lower T staging (p = 0.008) and lower Ki-67 LI
(p = 0.008).
Correlation between expression profiles of proteins
associated with serine or glycine metabolism and
glycolysis-associated proteins
Previously, we reported differential expression patterns of
glycolysis-associated enzymes, including Glut-1, CA9, and mono-
carboxylate transporter 4 (MCT4) in tissues derived from different
breast cancer subtypes [10,17]. Here, we compared expression
profiles of these proteins with those associated with serine or
glycine metabolism to identify a possible link between these
metabolic pathways in the context of the breast cancer (Table 6
and Table 7). By correlation analyses, we found that expression of
glycolysis-associated and serine-/-glycine-metabolism–associated
enzymes were correlated in separate tumor components, tumoral
and stromal, as follows: tumoral Glut-1 and CA9 and tumoral
PHGDH, PSPH, and SHMT1 (p,0.05); tumoral CA9, MCT4,
and tumoral PSPH (p,0.001); stromal Glut-1 and tumoral PSPH
(p= 0.018), stromal PSPH (p,0.001) and stromal GLDC (p,
0.001); stromal CA9 and stromal PSPH (p,0.001), SHMT1 (p,
0.001), and GLDC (p,0.001); stromal MCT4 and tumoral
PHGDH (p,0.001), tumoral PSPH (p,0.001), stromal PSPH
Table 3. Expression of metabolism-associated enzymes according to breast cancer phenotype.
Parameters
Total (n = 709)
(%)
Luminal A (n=297)
(%)
Luminal B (n =168)
(%)
HER-2 (n=70)
(%)
TNBC (n=174)
(%) P-value
PHGDH in tumor ,0.001
Negative 452 (63.8) 253 (85.2) 124 (73.8) 33 (47.1) 42 (24.1)
Positive 132 (75.9) 44 (14.8) 44 (26.2) 37 (52.9) 132 (75.9)
PSAT1 in tumor 0.061
Negative 526 (74.2) 229 (77.1) 126 (75.0) 43 (61.4) 128 (73.6)
Positive 183 (25.8) 68 (22.9) 42 (25.0) 27 (38.6) 46 (26.4)
PSPH in tumor ,0.001
Negative 611 (86.2) 284 (95.6) 157 (93.5) 55 (78.6) 115 (66.1)
Positive 98 (13.8) 13 (4.4) 11 (6.5) 15 (21.4) 59 (33.9)
PSPH in stroma ,0.001
Negative 625 (88.2) 287 (96.6) 141 (83.9) 54 (77.1) 143 (82.2)
Positive 84 (11.8) 10 (3.4) 27 (16.1) 16 (22.9) 31 (17.8)
SHMT1 in tumor ,0.001
Negative 598 (84.3) 284 (95.6) 154 (91.7) 59 (84.3) 101 (58.0)
Positive 111 (15.7) 13 (4.4) 14 (8.3) 11 (15.7) 73 (42.0)
SHMT1 in stroma ,0.001
Negative 310 (43.7) 156 (52.5) 51 (30.4) 19 (27.1) 84 (48.3)
Positive 399 (56.3) 141 (47.5) 117 (69.6) 51 (72.9) 90 (51.7)
GLDC in tumor ,0.001
Negative 370 (52.2) 138 (46.5) 97 (57.7) 26 (37.1) 109 (62.6)
Positive 339 (47.8) 159 (53.5) 71 (42.3) 44 (62.9) 65 (37.4)
GLDC in stroma ,0.001
Negative 621 (87.6) 271 (91.2) 135 (80.4) 53 (75.7) 162 (93.1)
Positive 88 (12.4) 26 (8.8) 33 (19.6) 17 (24.3) 12 (6.9)
TNBC, triple negative breast cancer.
doi:10.1371/journal.pone.0101004.t003
Serine/Glycine Metabolism in Breast Cancer
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(p,0.001), stromal SHMT1 (p,0.001), and stromal GLDC (p,
0.001).
Impact of serine-/glycine-metabolism–associated
enzymes on patients’ prognosis
Statistics was used to assess the effect of the expression of the
metabolism-associated enzymes on patients’ survival and prognos-
tic parameters. By univariate analysis, tumoral PSPH positivity
(p = 0.042) and tumoral GLDC negativity (p = 0.049) were
associated with short disease-free survival (DFS) and tumoral
PHGDH positivity (p = 0.019), tumoral PSPH positivity
(p = 0.005), stromal PSPH positivity (p = 0.004), and stromal
SHMT1 negativity (p = 0.020) were associated with short overall
survival (OS) (Table 8 and Figure 5).
By multivariate Cox analysis, high T staging (T1 vs. T2/3,
hazard ratio: 2.245, 95% CI: 1.212–4.160, p = 0.01) and lymph-
node metastasis (hazard ratio: 2.574, 95% CI: 1.513–4.379, p,
0.001) were associated with short DFS (Table 9). Meanwhile,
lymph-node metastasis (hazard ratio: 2.204, 95% CI: 1.284–3.782,
p = 0.004), tumoral PSPH positivity (hazard ratio: 2.068, 95% CI:
1.049–4.079, p = 0.036), stromal PSPH positivity (hazard ratio:
2.152, 95% CI: 1.107–4.184, p = 0.024), and stromal SHMT1
negativity (hazard ratio: 2.142, 95% CI: 1.219–3.764, p= 0.008)
were associated with short OS.
Next, we examined the correlation between the expression of
the enzymes associated with serine/glycine metabolism and
survival of breast cancer patients by molecular subtypes. By
univariate analysis, patients with each molecular subtype showed
unfavorable OS in accordance with expression profiles of the
following proteins (Table S1 in File S1): tumoral PHGDH
positivity (p = 0.033), tumoral PSPH positivity (p = 0.020), and
stromal SHMT1 negativity (p = 0.026) in the luminal-A; stromal
PSPH positivity (p = 0.041) in the HER-2; and stromal SHMT1
negativity (p = 0.040) in the TNBC subtype. In addition, tumoral
PSPH positivity (p = 0.042) and stromal SHMT1 negativity
(p = 0.009) in the TNBC subtype were associated with unfavorable
DFS.
By multivariate Cox analysis (Tabel S2), tumoral PSPH
positivity (hazard ratio: 7.067, 95% CI: 1.316–37.95, p= 0.023)
and stromal SHMT1 negativity (hazard ratio: 5.300, 95% CI:
1.101–25.50, p = 0.037) were associated with short OS in the
luminal-A subtype; lymph-node metastasis (hazard ratio: 17.51,
95% CI: 1.969–155.8, p = 0.010) was correlated with short DFS,
and lymph-node metastasis (hazard ratio: 21.49, 95% CI: 2.434–
189.7, p = 0.006) and ER negativity (hazard ratio: 14.38, 95% CI:
1.171–176.7, p= 0.037) were correlated with short OS in the
luminal-B subtype; lymph-node metastasis (hazard ratio: 6.456,
95% CI: 2.376–17.54, p,0.001), tumoral PHGDH negativity
(hazard ratio: 3.358, 95% CI: 1.448–8.866, p = 0.006), tumoral
PSPH positivity (hazard ratio: 6.173, 95% CI: 2.323–16.40, p,
0.001), stromal SHMT1 negativity (hazard ratio: 3.312, 95% CI:
1.256–8.736, p= 0.016), and tumoral GLDC negativity (hazard
ratio: 4.231, 95% CI: 1.384–12.92, p = 0.011) correlated with
short DFS in TNBC subtype. In addition, lymph-node metastasis
(hazard ratio: 2.799, 95% CI: 1.119–7.002, p = 0.028), tumoral
PHGDH negativity (hazard ratio: 3.624, 95% CI: 1.500–8.757,
Figure 5. Disease-free and overall survival according to the expression of enzymes associated with serine/glycine metabolism.
doi:10.1371/journal.pone.0101004.g005
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p= 0.004), tumoral PSPH positivity (hazard ratio: 3.880, 95% CI:
1.495–10.07, p= 0.005), and stromal SHMT1 negativity (hazard
ratio: 2.605, 95% CI: 1.024–6.626, p = 0.044) correlated with
short OS in TNBC subtype.
Discussion
In this study, we examined differential expression patterns of
some of the enzymes associated with serine/glycine metabolism in
the different molecular subtypes of the breast cancer in separate
histopathological tumor compartments (i.e., cancer cell and tumor
stroma) and investigated their likely clinical implications. Enzymes
associated with serine metabolism, including PHGDH and PSPH
were highly expressed in the TNBC cell lines and tissues, but not
significantly expressed in the luminal-A subtype. Previous studies
have reported increased expression of PHGDH especially in the
ER-negative cancers, showing an expression rate about 70% [3].
We also confirmed that PHGDH was highly expressed in the
TNBC subtype, representative ER-negative breast cancers.
PHGDH was expressed in 68.1% of the ER-negative cancers in
comparison with 18.5% in the ER-positive cancers and was
associated with high histologic grading, ER negativity, PR
negativity, and high Ki-67 LI, which are known as poor
prognosticators. Similar to PHGDH, PSPH was frequently
expressed in the TNBC subtype and correlated with high
histopathological grading, ER negativity, PR negativity, and high
Ki-67 LI. Thus, we hypothesize that a breast cancer subset with
high expression of enzymes associated with serine metabolism
(PHGDH and PSPH) could present with an aggressive behavior. It
is likely that metabolic demand for serine metabolites may increase
as the overall metabolic demand increases in breast cancers with
aggressive pathological behavior.
Previous reports demonstrated that the glycolysis-associated
enzymes, such as Glut-1, CA9, and MCT4, were distinctly
expressed in different molecular subtypes: high in the TNBC and
basal-like, but low in the luminal-A subtype [9,10]. This study
showed that expression of Glut-1 and CA9 were linked to
PHGDH and PSPH expression, which could be explained because
serine metabolites serve as glycolytic intermediates. Thus, serine
metabolism provides a-ketoglutarate, a TCA-cycle intermediate,
to cancer cells instead of serine itself, leading to acceleration of
mitochondrial metabolism using excess a-ketoglutarate by highly
expressed enzymes which drive mitochondrial energy metabolism
[3].
Similar to PHGDH and PSPH, SHMT1 was highly expressed
in the TNBC subtype and lowest in the luminal-A subtype. As
previously reported, glycine metabolism is key in accelerating
cancerous cell proliferation; we believe that high SHMT1 levels in
the TNBC subtype ensures high proliferative capacity, showing
the highest Ki-67 LI among other molecular subtypes [5].
Table 8. Impact of expression of enzymes associated with serine/glycine metabolism on disease-free and overall survival tested by
log-rank analysis.
Parameters Number of patients/recurrence/death Disease-free survival Overall survival
Mean survival (95% CI)
months P-value
Mean survival (95% CI)
months P-value
PHGDH in tumor 0.137 0.019
Negative 452/36/31 128 (125–132) 132 (129–135)
Positive 257/27/28 120 (113–127) 123 (118–128)
PSAT1 in tumor 0.507 0.225
Negative 526/43/38 126 (123–129) 129 (126–132)
Positive 183/20/21 124 (118–130) 127 (122–132)
PSPH in tumor 0.042 0.005
Negative 611/50/45 128 (125–131) 131 (128–133)
Positive 98/13/14 107 (99–115) 117 (108–126)
PSPH in stroma 0.097 0.004
Negative 625/52/46 126 (122–130) 131 (128–133)
Positive 84/11/13 117 (107–127) 116 (106–125)
SHMT1 in tumor 0.208 0.091
Negative 598/50/46 127 (124–130) 130 (127–133)
Positive 111/13/13 121 (112–130) 125 (117–132)
SHMT1 in stroma 0.107 0.020
Negative 310/34/35 121 (115–127) 126 (121–130)
Positive 399/29/24 128 (124–132) 131 (128–134)
GLDC in tumor 0.049 0.377
Negative 370/42/36 122 (116–127) 129 (125–132)
Positive 339/21/23 130 (126–134) 131 (127–135)
GLDC in stroma 0.568 0.951
Negative 621/54/52 126 (122–130) 130 (127–132)
Positive 88/9/7 115 (106–124) 123 (116–130)
doi:10.1371/journal.pone.0101004.t008
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GLDC was also expressed at differing levels in different
molecular subtypes of breast cancer. The highest GLDC
expression was found in the HER-2 and the lowest in the TNBC
subtype, in contrast to enzymes involved in the serine metabolism.
High GLDC levels have been reported in several human cancers,
including non-small-cell lung carcinoma, ovarian cancer, and
germ-cell tumors; however, GLDC levels have not been studied in
breast cancer [4]. The precise mechanism of increased GLDC in
HER-2 subtype could not be postulated, but GLDC levels were
previously examined in MCF10A cells after oncogenic transfor-
mation by KRASG12D, PIK3CAE545K, or MYCT58A. All three
oncogenes increased GLDC expression by 20-fold, suggesting that
oncogene-induced GLDC transcription can commonly be driven
by oncogenic Ras, PI3K, and Myc [4]. Therefore, we hypothesize
that the TNBC subtype, which is not associated with any well-
known driving oncogene, revealed the lowest GLDC level, unlike
the HER-2 subtype driven by certain HER-2 oncogenes.
Appreciably, breast cancer stromal components expressed
elevated PSPH, SHMT1, and GLDC levels. According to the
‘‘reverse Warburg effect’’ theory, both the stromal and epithelial
tumor components are involved in cancer metabolism: oxidative
phosphorylation by the functional mitochondria occurs in the
epithelial tumor component; glycolysis due to increased autoph-
agic activity leads to dysfunctional mitochondria in the stromal
component [18,19,20,21]. Similar to the epithelial tumor compo-
nent, the stromal component expressed the highest levels of PSPH,
SHMT1, and GLDC in the HER-2 and lowest in TNBC subtype.
Expression of these enzymes was statistically correlated with
expression of glycolysis-associated enzymes such as Glut-1, CA9,
and MCT-4, supporting the possibility of serine/glycine metab-
olism occurring in the tumor stroma. Although the exact
mechanisms underlying high levels of the enzymes associated
with serine/glycine metabolism in the HER-2 subtype are
unknown, the glutaminolysis-associated enzymes, including gluta-
minase 1 (GLS1), glutamate dehydrogenase (GDH), and amino
acid transporter 2 (ASCT2), have been highly expressed in the
HER-2 subtype, suggesting that tumor stromal cells in this subtype
are active metabolically [11].
We also examined the potential clinical implications of the
expression profiles metabolism-associated enzymes in the different
molecular subtypes of breast cancer. Particularly, expression of
enzymes associated with serine/glycine metabolism was correlated
with patients’ prognosis. In the entire patient population
irrespective of subtype, tumoral PSPH positivity, stromal PSPH
positivity, and stromal SHMT1 negativity were independent
factors for poor prognosis. According to the molecular subtype,
tumoral PSPH positivity and stromal SHMT1 negativity in the
luminal-A subtype and tumoral PHGDH negativity, tumoral
PSPH positivity, and stromal SHMT1 negativity in the TNBC
subtype were independent factors for poor prognosis. Although
correlations between levels of enzymes associated with serine/
glycine metabolism and tumor prognosis have remained unknown,
several previous studies have shown that high levels of glycolysis-
associated enzymes, including Glut-1 and CA9, were correlated
with unfavorable prognosis in breast cancer [9,22,23].
Although high SHMT2, but not SHMT1, was correlated with
breast cancer patient mortality [5], we found that stromal SHMT1
negativity was associated with poor prognosis. Similarly, tumoral
Table 9. Multivariate analysis of breast cancer survival.
Included parameters Disease-free survival Overall survival
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
T stage 0.010 0.101
T1 versus T2–3 2.245 1.212–4.160 1.656 0.906–3.024
N stage ,0.001 0.004
N0 versus N1–3 2.574 1.513–4.379 2.204 1.284–3.782
Histologic grade 0.271 0.990
I/II versus III 1.365 0.785–2.374 1.004 0.562–1.791
ER status 0.129 0.322
Negative versus Positive 1.849 0.836–4.089 1.495 0.675–3.311
PR status 1.298 0.141
Negative versus Positive 1.298 0.595–2.833 1.839 0.817–4.140
HER-2 status 0.097 0.112
Negative versus Positive 1.645 0.913–2.962 1.638 0.891–3.012
PHGDH in tumor 0.367 0.932
Negative versus Positive 0.754 0.409–1.393 0.973 0.520–1.819
PSPH in tumor 0.069 0.036
Negative versus Positive 1.911 0.952–3.836 2.068 1.049–4.079
PSPH in stroma 0.399 0.024
Negative versus Positive 1.345 0.676–2.677 2.152 1.107–4.184
SHMT1 in stroma 0.141 0.008
Negative versus Positive 1.490 0.876–2.532 2.142 1.219–3.764
GLDC in tumor 1.654 0.634
Negative versus Positive 1.654 0.935–2.925 1.149 0.649–2.033
doi:10.1371/journal.pone.0101004.t009
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PHGDH negativity in the TNBC subtype was correlated with
poor prognosis. However, further studies are needed to confirm
these findings. In conclusion, we identified differential expression
of the enzymes associated with serine/glycine metabolism
according to breast cancer molecular subtypes. The highest
expression of enzymes associated with serine metabolism was
found in the TNBC subtype, and the lowest, in the luminal-A
subtype. Expression of enzymes associated with glycine metabo-
lism was high in the HER-2 type in both tumor and stromal
compartments.
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